-- Combined company creates generics growth engine with technical capabilities to bring complex, high-value products to market in efficient and cost effect manner -- -- Proven track record with ...
Amid the dozens of publicly traded firms in Minnesota, Baudette-based ANI Pharmaceuticals Inc. often flies under the radar. The pharmaceutical company about five hours north of Minneapolis has grown ...
ANI Pharmaceuticals, Inc. delivered robust 2025 results and issued bullish 2026 guidance. Learn more about ANIP stock here.
ANI is growing its capabilities and pipeline with an acquisition. The company has signed a definitive agreement to acquire Novitium Pharma for $163.5 million, including $89.5 million in cash and $74 ...
ANI Pharmaceuticals offers an asymmetric opportunity in small-cap pharma, with a niche in generics, rare disease treatments, and contract manufacturing. Despite cash burn concerns, ANI's revenue ...
-- ANI Pharmaceuticals appoints Mary Pao, M.D., Ph.D., as Chief Medical Officer, Rare Disease, and Elizabeth Powell, J.D., as Chief Compliance Officer and Head of ...
ANI Pharmaceuticals has paid $17.25 million to buy out royalty obligations for ILUVIEN and YUTIQ, enhancing financial flexibility. ANI Pharmaceuticals incurred a one-time payment of $17.25 million to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results